Suven Life Sciences Limited SUVEN NSEPHARMA
Company Overview
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Recent Developments
- Mar 2026 Revenue of ₹7.11 Cr (+6.9% YoY); net profit ₹-276.34 Cr.
- Trailing 12 Months Year-on-year growth — revenue +6.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -19.3%, profit CAGR -44.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -19.30% |
| 1 Year: | 6.89% |
Compounded Profit Growth
| 5 Years: | -44.55% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +32.22% |
| 6 Months: | +131.48% |
| 3 Months: | +82.12% |
| 1 Month: | +32.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)71.96 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -19.3% CAGR over 5 years.
- Earnings shrank at -44.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SUVEN Suven Life Sciences Limited NSEPHARMA | 357.10 | -29.44 | ₹9,417.46 Cr | 0.00% | -46.55% | -46.73% | -19.30% | -44.55% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.00 Cr | 4.00 Cr | 3.00 Cr | 2.00 Cr | 2.00 Cr | 1.00 Cr | 3.00 Cr | - | 1.47 Cr | 1.87 Cr | 91.92 L | 2.81 Cr | 1.52 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | - | - | - | - | - | - | - | - | 1.47 Cr | 1.87 Cr | 91.92 L | 2.81 Cr | 1.52 Cr |
| Operating Expenses | 34.00 Cr | 32.00 Cr | 27.00 Cr | 49.00 Cr | 33.00 Cr | 32.00 Cr | 55.00 Cr | - | 46.63 Cr | 53.98 Cr | 82.01 Cr | 107.50 Cr | 53.74 Cr |
| Operating Income | -34.00 Cr | -30.00 Cr | -26.00 Cr | -48.00 Cr | -32.00 Cr | -32.00 Cr | -53.00 Cr | - | -45.17 Cr | -52.12 Cr | -81.09 Cr | -104.70 Cr | -52.22 Cr |
| EBITDA | -32.00 Cr | -28.00 Cr | -24.00 Cr | -46.00 Cr | -30.00 Cr | -31.00 Cr | -52.00 Cr | - | -42.60 Cr | -50.15 Cr | -75.99 Cr | -100.58 Cr | -43.86 Cr |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 15.78 L |
| Pretax Income | -28.00 Cr | -24.00 Cr | -13.00 Cr | -42.00 Cr | -28.00 Cr | -28.00 Cr | -50.00 Cr | - | -43.94 Cr | -51.52 Cr | -77.31 Cr | -101.92 Cr | -45.60 Cr |
| Tax Provision | -0 | -0 | -0 | -0 | 1.12 Cr | -0 | -0 | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -28.00 Cr | -24.00 Cr | -13.00 Cr | -42.00 Cr | -27.00 Cr | -28.00 Cr | -50.00 Cr | - | -43.94 Cr | -51.52 Cr | -77.31 Cr | -101.92 Cr | -45.60 Cr |
| Diluted EPS | -1.27 | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | - | -2.02 | -2.36 | -3.48 | -4.55 | -2.02 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 521.00 Cr | 499.00 Cr | 543.00 Cr | 625.00 Cr | 286.00 Cr | 13.00 Cr | 13.00 Cr | - | 13.54 Cr | 11.69 Cr | 6.66 Cr | 7.11 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 36.78 L | 71.79 L | 0 | 0 |
| Gross Profit | - | - | - | - | - | - | - | - | 13.17 Cr | 10.98 Cr | 6.66 Cr | 7.11 Cr |
| Operating Expenses | 361.00 Cr | 398.00 Cr | 414.00 Cr | 427.00 Cr | 300.00 Cr | 128.00 Cr | 93.00 Cr | - | 145.09 Cr | 145.27 Cr | 178.25 Cr | 297.23 Cr |
| Operating Income | 147.00 Cr | 84.00 Cr | 108.00 Cr | 177.00 Cr | -25.00 Cr | -120.00 Cr | -84.00 Cr | - | -131.92 Cr | -134.30 Cr | -171.60 Cr | -290.12 Cr |
| EBITDA | 159.00 Cr | 102.00 Cr | 129.00 Cr | 198.00 Cr | -14.00 Cr | -116.00 Cr | -80.00 Cr | - | -111.44 Cr | -99.42 Cr | -154.88 Cr | -270.57 Cr |
| Interest Expense | 5.00 Cr | 6.00 Cr | 6.00 Cr | 5.00 Cr | 2.00 Cr | 1.00 Cr | 1.00 Cr | - | 28.92 L | 15.84 L | 4.66 L | 15.78 L |
| Pretax Income | 152.00 Cr | 98.00 Cr | 123.00 Cr | 196.00 Cr | 0 | -106.00 Cr | -77.00 Cr | - | -118.27 Cr | -106.08 Cr | -160.75 Cr | -276.34 Cr |
| Tax Provision | 42.56 Cr | 25.48 Cr | 35.67 Cr | 72.52 Cr | 0 | 11.66 Cr | 5.39 Cr | - | 0 | -1.00 Cr | 0 | 0 |
| Net Income | 109.00 Cr | 72.00 Cr | 87.00 Cr | 124.00 Cr | -24.00 Cr | -94.00 Cr | -72.00 Cr | - | -118.27 Cr | -105.08 Cr | -160.75 Cr | -276.34 Cr |
| Diluted EPS | 5.70 | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | - | -6.63 | -4.82 | -7.37 | -12.13 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 773.00 Cr | 751.00 Cr | 816.00 Cr | 919.00 Cr | 303.00 Cr | 182.00 Cr | 128.00 Cr | - | 388.91 Cr | 284.90 Cr | 135.18 Cr | 624.21 Cr |
| Current Assets | - | - | - | - | - | - | - | - | 251.59 Cr | 256.67 Cr | 75.47 Cr | 546.71 Cr |
| Cash & Equivalents | - | - | - | - | - | - | - | - | 37.02 Cr | 14.93 Cr | 15.03 Cr | 8.28 Cr |
| Inventory | - | - | - | - | - | - | - | - | 0 | 70.84 L | 23.75 L | 10.20 L |
| Receivables | - | - | - | - | - | - | - | - | 80.74 L | 1.29 Cr | 1.34 Cr | 1.51 Cr |
| Total Liabilities | - | - | - | - | - | - | - | - | 13.59 Cr | 14.86 Cr | 25.20 Cr | 32.81 Cr |
| Current Liabilities | - | - | - | - | - | - | - | - | 11.13 Cr | 13.52 Cr | 23.49 Cr | 30.90 Cr |
| Long Term Debt | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - |
| Total Debt | 109.00 Cr | 83.00 Cr | 71.00 Cr | 34.00 Cr | 3.00 Cr | 6.00 Cr | 5.00 Cr | - | 1.61 Cr | 70.97 L | 0 | 16.69 Cr |
| Total Equity | 560.00 Cr | 596.00 Cr | 667.00 Cr | 768.00 Cr | 239.00 Cr | 144.00 Cr | 108.00 Cr | - | 375.32 Cr | 270.04 Cr | 109.99 Cr | 591.40 Cr |
| Shares Outstanding | - | - | - | - | - | - | - | - | 21.81 Cr | 21.81 Cr | 21.81 Cr | 26.37 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 143.00 Cr | 68.00 Cr | 109.00 Cr | 70.00 Cr | -53.00 Cr | -135.00 Cr | -96.00 Cr | - | -115.98 Cr | -82.62 Cr | -154.10 Cr | -301.79 Cr |
| Investing Cash Flow | -110.00 Cr | -39.00 Cr | -311.00 Cr | -1.00 Cr | 30.00 Cr | 146.00 Cr | 56.00 Cr | - | -247.81 Cr | 61.59 Cr | 154.95 Cr | -462.11 Cr |
| Financing Cash Flow | 179.00 Cr | -68.00 Cr | -30.00 Cr | -52.00 Cr | 5.00 Cr | 3.00 Cr | 35.00 Cr | - | 395.54 Cr | -1.05 Cr | -75.63 L | 757.15 Cr |
| Capital Expenditure | -118.00 Cr | -58.00 Cr | -30.00 Cr | -42.00 Cr | -39.00 Cr | -2.00 Cr | -6.00 Cr | -19.77 Cr | -2.89 Cr | - | -37.28 Cr | -5.08 Cr |
| Free Cash Flow | 25.00 Cr | 10.00 Cr | 79.00 Cr | 28.00 Cr | -92.00 Cr | -137.00 Cr | -102.00 Cr | - | -118.88 Cr | -82.62 Cr | -191.38 Cr | -306.87 Cr |
| Net Change in Cash | 212.00 Cr | -39.00 Cr | -232.00 Cr | 17.00 Cr | -18.00 Cr | 14.00 Cr | -5.00 Cr | - | 31.75 Cr | -22.09 Cr | 9.31 L | -6.75 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 97.3% | 93.9% | 100.0% | 100.0% |
| Operating Margin % | 28.2% | 16.8% | 19.9% | 28.3% | -8.7% | -923.1% | -646.2% | - | -974.3% | -1,148.5% | -2,578.1% | -4,077.7% |
| Net Margin % | 20.9% | 14.4% | 16.0% | 19.8% | -8.4% | -723.1% | -553.8% | - | -873.5% | -898.6% | -2,415.1% | -3,884.1% |
| ROE % | 19.5% | 12.1% | 13.0% | 16.1% | -10.0% | -65.3% | -66.7% | - | -31.5% | -38.9% | -146.1% | -46.7% |
| ROCE % | - | - | - | - | - | - | - | - | -34.9% | -49.5% | -153.6% | -48.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SUVEN
Here's Why We're Not Too Worried About Suven Life Sciences' (NSE:SUVEN) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPRUhtaENZSmVLVzdLVERBQjdUYm8xT0dXVXREN0RNYTNvdkgzN0xoaWRqNWRxSlBTaE5VaXVTT2E4SVlIal9kQy1qVFpwN1NOa1B5ajFkX3Z3ZXBBYjhhd3JHWVU2bVp3b0wxbmhqLUxxdGE2V05leFJuU1FneWw2S3lWbWptbVJBLUNZX2…
Suven Life Sciences to host analyst meet on Jul 17 - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT0dEZ3dsU3Zpdnl6RjRXTDdTcWVfcDcxWnZ1cWhZOXJQYkxMbkRHeVlMaFRMTlZhSk9XaDltTmVBWWNWUm94Q2p2cFR4Z0tLMFBXLW9SWjZ1Sm5sSFV1SGJISWVra0ZERC1fMVViSC03Y0JLaXBqY3JlSGZGWmRjVml3WDZMSVdkdTVUSV…
Price to earnings forward of Suven Life Sciences Limited – NSE:SUVEN - TradingView
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPeTJzOUsybkVRdHE3ek5yNXJ6LTRHcE5NMU5zTjB3TEJiMmdzbWtQQmItbm4zMVR1ZDUydmJXcm1QTFFOWGdrdUxNd1dXeFFJdHExaFJacHYzV1JlMko5VUg2Vk5SakJMZVNBTkhBdF94MThQOEdTc0lVTlhVc0JOTTE4cWlzOW9HQUk3NV…
Market Trading Guide: Suven Life Sciences among 2 stock recommendations for Friday - The Economic Times
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOUVFpQ01aSHZMNVpRUldGR29JZUM2dGV1a1NXdEI5NVNQZ1FVdkVXTURJWG1Ea2VzOE9Mei1ES3daVm9QMER6OVl6RHpudGdpUTVQdTB5MEluOFNwZkRWWEF1bUpDVVQ0V2JIUjJHcG5xbDZzNDV4UkdyRDY2bFBQQTVHVDBkY1p5Yk1pel…
Suven Life Completes SUVN-16107 Phase-1 Study - HDFC Sky
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNV3VQcEJLYWNNWFluVVVvYVByVVFpWTVKdzhEOEtSS3BkMDFWbERrSEx1M0tGRWE4cmtKZENTajJGejVNRnRBUkY5LThFaFJYc190MndDUVFKM2FJMzJhLUxBeHFvRUotUk1JT0pnYjFCanBRb09VMXpPcDNtWmdzaDhWTWMwSTlsaFFUaG…
Suven Life faces make-or-break FY27 as brain disorder bets near readouts - Moneycontrol.com
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNRFNUdUtpWnJJdkFMMEJ3bm1SSzVOb1hYWE9zMklULU1UZ0VXVzktbzViM1BhWWlVSXNIa1JUU1NjWFhmcnBEWXZZSDBKSG9zSVFtRFY3SEtHdkhHUnpNMXFsV3FwOUs5dEgxTml0UFJVQnl0UUdtMUVleFpwV2xIZDZXMm92UWVnWUhfTU…
SUVEN — Frequently Asked Questions
What is the current share price of Suven Life Sciences Limited (SUVEN)?
As of 2026-07-15 09:52 IST, Suven Life Sciences Limited (SUVEN) trades at ₹357.10 on NSE. Its 52-week range is ₹126.65 to ₹359.55.
What is the market capitalisation of SUVEN?
Suven Life Sciences Limited (SUVEN) has a market capitalisation of ₹9,417.46 Cr on NSE.
What is the P/E ratio of SUVEN?
SUVEN trades at a trailing price-to-earnings (P/E) ratio of -29.44. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 13.72.
What is the return on equity (ROE) of SUVEN?
SUVEN has a return on equity (ROE) of -46.73%. Its return on capital employed (ROCE) is -46.55%.
Is SUVEN a good stock to buy?
This page provides a data-driven analysis of Suven Life Sciences Limited (SUVEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.